US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Applied DNA Sciences, Inc. - Common Stock (NQ:APDN)

5.620 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Applied DNA Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX’ Reflecting Digital Asset Treasury Strategy
From Applied DNA Sciences, Inc.
Via Business Wire
News headline image
Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation
From Applied DNA Sciences, Inc.
Via Business Wire
News headline image
Applied DNA Abstracts Selected for Poster Presentations Showcasing LineaDNA and LineaIVT Platforms at Upcoming mRNA and CAR T Industry Conferences
Via ACCESS Newswire
News headline image
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
Via ACCESS Newswire
News headline image
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
Via ACCESS Newswire
News headline image
Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
Via ACCESS Newswire
News headline image
Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application
Via ACCESS Newswire
News headline image
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
Via ACCESS Newswire
News headline image
Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
Via ACCESS Newswire
News headline image
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
Via ACCESSWIRE
News headline image
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
Via ACCESS Newswire
News headline image
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August
Via ACCESS Newswire
News headline image
Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
Via ACCESS Newswire
News headline image
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
Via ACCESS Newswire
News headline image
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
Via ACCESS Newswire
News headline image
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
Via ACCESS Newswire
News headline image
Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
Via ACCESS Newswire
News headline image
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESS Newswire
News headline image
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
Via ACCESS Newswire
News headline image
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
Via ACCESS Newswire
News headline image
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
Via ACCESS Newswire
News headline image
Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14
Via ACCESS Newswire
News headline image
Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
Via ACCESSWIRE
News headline image
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
Via ACCESSWIRE
News headline image
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
Via ACCESSWIRE
News headline image
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
Via ACCESSWIRE
News headline image
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
Via ACCESSWIRE
News headline image
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
Via ACCESSWIRE
News headline image
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESSWIRE
News headline image
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 Next >